Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ...
The kinase AKT1 is a key effector of the phosphoinositide 3-kinase signal transduction pathway, which drives cell proliferation and is aberrantly activated in diverse tumours. A study in Nature ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results